1. Home
  2. ELVN vs DAVE Comparison

ELVN vs DAVE Comparison

Compare ELVN & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • DAVE
  • Stock Information
  • Founded
  • ELVN 2016
  • DAVE 2017
  • Country
  • ELVN United States
  • DAVE United States
  • Employees
  • ELVN N/A
  • DAVE N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • DAVE Retail: Computer Software & Peripheral Equipment
  • Sector
  • ELVN Health Care
  • DAVE Technology
  • Exchange
  • ELVN Nasdaq
  • DAVE Nasdaq
  • Market Cap
  • ELVN 1.2B
  • DAVE 3.2B
  • IPO Year
  • ELVN 2020
  • DAVE N/A
  • Fundamental
  • Price
  • ELVN $19.30
  • DAVE $224.02
  • Analyst Decision
  • ELVN Strong Buy
  • DAVE Strong Buy
  • Analyst Count
  • ELVN 5
  • DAVE 6
  • Target Price
  • ELVN $41.20
  • DAVE $262.17
  • AVG Volume (30 Days)
  • ELVN 489.5K
  • DAVE 376.1K
  • Earning Date
  • ELVN 11-12-2025
  • DAVE 11-11-2025
  • Dividend Yield
  • ELVN N/A
  • DAVE N/A
  • EPS Growth
  • ELVN N/A
  • DAVE 70.95
  • EPS
  • ELVN N/A
  • DAVE 3.84
  • Revenue
  • ELVN N/A
  • DAVE $433,065,000.00
  • Revenue This Year
  • ELVN N/A
  • DAVE $48.07
  • Revenue Next Year
  • ELVN $20.05
  • DAVE $15.28
  • P/E Ratio
  • ELVN N/A
  • DAVE $56.76
  • Revenue Growth
  • ELVN N/A
  • DAVE 47.97
  • 52 Week Low
  • ELVN $13.30
  • DAVE $36.67
  • 52 Week High
  • ELVN $30.03
  • DAVE $286.45
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 46.63
  • DAVE 56.71
  • Support Level
  • ELVN $18.01
  • DAVE $206.54
  • Resistance Level
  • ELVN $20.30
  • DAVE $230.37
  • Average True Range (ATR)
  • ELVN 1.10
  • DAVE 12.26
  • MACD
  • ELVN -0.12
  • DAVE 2.00
  • Stochastic Oscillator
  • ELVN 39.82
  • DAVE 82.45

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About DAVE Dave Inc.

Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.

Share on Social Networks: